Trial watch: anticancer vaccination with dendritic cells
Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-speci...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412876 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142194237308928 |
|---|---|
| author | Francisca Borges Raquel S. Laureano Isaure Vanmeerbeek Jenny Sprooten Octavie Demeulenaere Jannes Govaerts Lisa Kinget Saurabh Saraswat Benoit Beuselinck Steven De Vleeschouwer Paul Clement Frederik De Smet Rüdiger V. Sorg Angeliki Datsi Nathalie Vigneron Stefan Naulaerts Abhishek D. Garg |
| author_facet | Francisca Borges Raquel S. Laureano Isaure Vanmeerbeek Jenny Sprooten Octavie Demeulenaere Jannes Govaerts Lisa Kinget Saurabh Saraswat Benoit Beuselinck Steven De Vleeschouwer Paul Clement Frederik De Smet Rüdiger V. Sorg Angeliki Datsi Nathalie Vigneron Stefan Naulaerts Abhishek D. Garg |
| author_sort | Francisca Borges |
| collection | DOAJ |
| description | Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology. |
| format | Article |
| id | doaj-art-62ea562a7fa84a7596a062de5d9f27c9 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-62ea562a7fa84a7596a062de5d9f27c92024-12-03T13:49:35ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2412876Trial watch: anticancer vaccination with dendritic cellsFrancisca Borges0Raquel S. Laureano1Isaure Vanmeerbeek2Jenny Sprooten3Octavie Demeulenaere4Jannes Govaerts5Lisa Kinget6Saurabh Saraswat7Benoit Beuselinck8Steven De Vleeschouwer9Paul Clement10Frederik De Smet11Rüdiger V. Sorg12Angeliki Datsi13Nathalie Vigneron14Stefan Naulaerts15Abhishek D. Garg16Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumDepartment of Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumResearch Group Experimental Neurosurgery and Neuroanatomy, Department of Neurosciences, KU Leuven, Leuven, BelgiumDepartment of Oncology, KU Leuven, Leuven, BelgiumLaboratory for Precision Cancer Medicine, Translational Cell and Tissue Unit, Department of Imaging and Pathology, KU Leuven, Leuven, BelgiumInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich Heine University Hospital, Düsseldorf, GermanyInstitute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, Heinrich Heine University Hospital, Düsseldorf, GermanyLudwig Institute for Cancer Research and Cellular Genetics Unit, Université de Louvain, Brussels, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumCell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, BelgiumDendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412876Antigen cross-presentationclinical trialDAMPsdendritic cellsimmune checkpoint blockersT cell priming |
| spellingShingle | Francisca Borges Raquel S. Laureano Isaure Vanmeerbeek Jenny Sprooten Octavie Demeulenaere Jannes Govaerts Lisa Kinget Saurabh Saraswat Benoit Beuselinck Steven De Vleeschouwer Paul Clement Frederik De Smet Rüdiger V. Sorg Angeliki Datsi Nathalie Vigneron Stefan Naulaerts Abhishek D. Garg Trial watch: anticancer vaccination with dendritic cells OncoImmunology Antigen cross-presentation clinical trial DAMPs dendritic cells immune checkpoint blockers T cell priming |
| title | Trial watch: anticancer vaccination with dendritic cells |
| title_full | Trial watch: anticancer vaccination with dendritic cells |
| title_fullStr | Trial watch: anticancer vaccination with dendritic cells |
| title_full_unstemmed | Trial watch: anticancer vaccination with dendritic cells |
| title_short | Trial watch: anticancer vaccination with dendritic cells |
| title_sort | trial watch anticancer vaccination with dendritic cells |
| topic | Antigen cross-presentation clinical trial DAMPs dendritic cells immune checkpoint blockers T cell priming |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412876 |
| work_keys_str_mv | AT franciscaborges trialwatchanticancervaccinationwithdendriticcells AT raquelslaureano trialwatchanticancervaccinationwithdendriticcells AT isaurevanmeerbeek trialwatchanticancervaccinationwithdendriticcells AT jennysprooten trialwatchanticancervaccinationwithdendriticcells AT octaviedemeulenaere trialwatchanticancervaccinationwithdendriticcells AT jannesgovaerts trialwatchanticancervaccinationwithdendriticcells AT lisakinget trialwatchanticancervaccinationwithdendriticcells AT saurabhsaraswat trialwatchanticancervaccinationwithdendriticcells AT benoitbeuselinck trialwatchanticancervaccinationwithdendriticcells AT stevendevleeschouwer trialwatchanticancervaccinationwithdendriticcells AT paulclement trialwatchanticancervaccinationwithdendriticcells AT frederikdesmet trialwatchanticancervaccinationwithdendriticcells AT rudigervsorg trialwatchanticancervaccinationwithdendriticcells AT angelikidatsi trialwatchanticancervaccinationwithdendriticcells AT nathalievigneron trialwatchanticancervaccinationwithdendriticcells AT stefannaulaerts trialwatchanticancervaccinationwithdendriticcells AT abhishekdgarg trialwatchanticancervaccinationwithdendriticcells |